Jason Bednar
Stock Analyst at Piper Sandler
(2.03)
# 3,126
Out of 5,049 analysts
186
Total ratings
35.21%
Success rate
-5.55%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SHC Sotera Health Company | Maintains: Neutral | $15 → $17 | $16.07 | +5.79% | 3 | Nov 5, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $87.19 | +25.02% | 14 | Oct 31, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $190 → $200 | $134.65 | +48.53% | 32 | Oct 30, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $145 → $153 | $125.19 | +22.21% | 2 | Sep 10, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $105 → $83 | $68.64 | +20.93% | 14 | Aug 28, 2025 | |
| SOLV Solventum | Maintains: Overweight | $87 → $94 | $67.16 | +39.96% | 7 | Aug 8, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $185 → $200 | $174.32 | +14.73% | 10 | Aug 8, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $141.38 | +48.54% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $19.63 | -3.18% | 13 | Aug 1, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.70 | +47.06% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $11.34 | +199.82% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $3.90 | -10.26% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $12.38 | +29.24% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $71.47 | +7.74% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.12 | +111.91% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $240.12 | +10.36% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $4.73 | +26.98% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.81 | +83.73% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $1.82 | +998.90% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $540.07 | -31.12% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $73.61 | +29.06% | 1 | Apr 19, 2023 |
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $16.07
Upside: +5.79%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $87.19
Upside: +25.02%
Align Technology
Oct 30, 2025
Reiterates: Overweight
Price Target: $190 → $200
Current: $134.65
Upside: +48.53%
ICU Medical
Sep 10, 2025
Maintains: Overweight
Price Target: $145 → $153
Current: $125.19
Upside: +22.21%
The Cooper Companies
Aug 28, 2025
Maintains: Overweight
Price Target: $105 → $83
Current: $68.64
Upside: +20.93%
Solventum
Aug 8, 2025
Maintains: Overweight
Price Target: $87 → $94
Current: $67.16
Upside: +39.96%
Becton, Dickinson and Company
Aug 8, 2025
Maintains: Neutral
Price Target: $185 → $200
Current: $174.32
Upside: +14.73%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $141.38
Upside: +48.54%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $19.63
Upside: -3.18%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.70
Upside: +47.06%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $11.34
Upside: +199.82%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $3.90
Upside: -10.26%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $12.38
Upside: +29.24%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $71.47
Upside: +7.74%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.12
Upside: +111.91%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $240.12
Upside: +10.36%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $4.73
Upside: +26.98%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.81
Upside: +83.73%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $1.82
Upside: +998.90%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $540.07
Upside: -31.12%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $73.61
Upside: +29.06%